Protalix Biotherapeutics Share Price Today
(NASDAQ: PLX)

Name: Protalix Biotherapeutics Share Price Today (NASDAQ: PLX) - Protalix Biotherapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Protalix Biotherapeutics share price is $2.37 & ₹206.12 as on 6 Mar 2025, 2.30 'hrs' IST

$2.37

▲

0.05

(2.16%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Protalix Biotherapeutics share price in Dollar and Rupees. Guide to invest in Protalix Biotherapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Protalix Biotherapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Protalix Biotherapeutics share price movements

Today's Low: $2.32
Today's High: $2.37
$2.37
2.11%
Downside
Day's Volatility :2.11%
Upside
0.0%
52 Weeks Low: $0.82
52 Weeks High: $2.76
$2.37
65.34%
Downside
52 Weeks Volatility :70.24%
Upside
14.13%

Protalix Biotherapeutics (PLX) Returns

Period	Protalix Biotherapeutics Inc	Index (Russel 2000)
3 Months	42.33%	0.0%
6 Months	127.45%	0.0%
1 Year	56.76%	0.0%
3 Years	45.91%	-11.6%

Protalix Biotherapeutics (PLX) Key Statistics

in dollars & INR

Previous Close	$2.32
Open	$2.33
Today's High	$2.37
Today's Low	$2.32
Market Capitalization	$170.1M
Today's Volume	$191.8K
52 Week High	$2.76
52 Week Low	$0.8214
Revenue TTM	$45.7M
EBITDA	$-7.6M
Earnings Per Share (EPS)	$-0.15
Profit Margin	-21.03%
Quarterly Earnings Growth YOY	-0.39%
Return On Equity TTM	-27.18%

How to invest in Protalix Biotherapeutics Stock (PLX) from India?

It is very easy for Indian residents to invest directly in Protalix Biotherapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Protalix Biotherapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Protalix Biotherapeutics or PLX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Protalix Biotherapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Protalix Biotherapeutics shares which would translate to 0.367 fractional shares of Protalix Biotherapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Protalix Biotherapeutics, in just a few clicks!

Returns in Protalix Biotherapeutics (PLX) for Indian investors in Rupees

The Protalix Biotherapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Protalix Biotherapeutics investment value today

Current value as on today

₹1,65,098

Returns

₹65,098

(+65.1%)

Returns from Protalix Biotherapeutics Stock

₹60,135 (+60.14%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Protalix Biotherapeutics (PLX)

-38%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Protalix Biotherapeutics Stock from India on INDmoney has decreased by -38% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Protalix Biotherapeutics

Buy

80%Buy

20%Hold

0%Sell

Based on 5 Wall street analysts offering stock ratings for Protalix Biotherapeutics(by analysts ranked 0 to 5 stars)

Based on 5 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Protalix Biotherapeutics Stock (PLX)

What analysts predicted

Upside of 511.81%

Target:

$14.50

Current:

$2.37

Insights on Protalix Biotherapeutics Stock (Ticker Symbol: PLX)

Price Movement
In the last 3 months, PLX stock has moved up by 42.3%
Increasing Revenue
Revenue is up for the last 3 quarters, 3.74M → 17.95M (in $), with an average increase of 48.6% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -6.04M → 3.23M (in $), with an average increase of 102.7% per quarter
PLX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 9.7%
Price to Sales
ForPLX every $1 of sales, investors are willing to pay $3.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

PLX Protalix Biotherapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$34.2M	↑ 77.94%
Net Income	$-26.5M	↓ 68.97%
Net Profit Margin	-77.27%	↑ 365.91%

	FY19	Y/Y Change
Revenue	$54.7M	↑ 59.73%
Net Income	$-26.2M	↓ 0.81%
Net Profit Margin	-47.98%	↑ 29.29%

	FY20	Y/Y Change
Revenue	$62.9M	↑ 15.0%
Net Income	$-14.9M	↓ 43.25%
Net Profit Margin	-23.68%	↑ 24.3%

	FY21	Y/Y Change
Revenue	$38.4M	↓ 39.03%
Net Income	$-34.0M	↑ 128.21%
Net Profit Margin	-88.62%	↓ 64.94%

	FY22	Y/Y Change
Revenue	$47.6M	↑ 24.22%
Net Income	$-14.9M	↓ 56.08%
Net Profit Margin	-31.33%	↑ 57.29%

	FY23	Y/Y Change
Revenue	$65.5M	↑ 37.48%
Net Income	$8.3M	↓ 155.68%
Net Profit Margin	12.69%	↑ 44.02%

	Q2 FY23	Q/Q Change
Revenue	$35.1M	↑ 265.82%
Net Income	$19.3M	↓ 717.66%
Net Profit Margin	55.14%	↑ 87.8%

	Q3 FY23	Q/Q Change
Revenue	$10.3M	↓ 70.51%
Net Income	$-1.9M	↓ 109.58%
Net Profit Margin	-17.9%	↓ 73.04%

	Q4 FY23	Q/Q Change
Revenue	$10.5M	↑ 1.36%
Net Income	$-6.0M	↑ 226.35%
Net Profit Margin	-57.64%	↓ 39.74%

	Q1 FY24	Q/Q Change
Revenue	$3.7M	↓ 64.26%
Net Income	$-4.6M	↓ 23.97%
Net Profit Margin	-122.6%	↓ 64.96%

	Q2 FY24	Q/Q Change
Revenue	$13.5M	↑ 259.5%
Net Income	$-2.2M	↓ 52.06%
Net Profit Margin	-16.35%	↑ 106.25%

	Q3 FY24	Q/Q Change
Revenue	$18.0M	↑ 33.29%
Net Income	$3.2M	↓ 246.89%
Net Profit Margin	18.02%	↑ 34.37%

	FY18	Y/Y Change
Profit	$24.9M	↑ 521.74%

	FY19	Y/Y Change
Profit	$43.8M	↑ 75.63%

	FY20	Y/Y Change
Profit	$52.0M	↑ 18.78%

	FY21	Y/Y Change
Profit	$22.0M	↓ 57.71%

	FY22	Y/Y Change
Profit	$28.0M	↑ 27.48%

	FY23	Y/Y Change
Profit	$42.5M	↑ 51.58%

	Q2 FY23	Q/Q Change
Profit	$28.9M	↑ 344.83%

	Q3 FY23	Q/Q Change
Profit	$5.5M	↓ 81.15%

	Q4 FY23	Q/Q Change
Profit	$1.6M	↓ 70.1%

	Q1 FY24	Q/Q Change
Profit	$1.1M	↓ 29.69%

	Q2 FY24	Q/Q Change
Profit	$4.0M	↑ 250.61%

	Q3 FY24	Q/Q Change
Profit	$9.6M	↑ 138.53%

	FY18	Y/Y Change
Operating Cash Flow	$-7.7M	↓ 22.53%
Investing Cash Flow	$-591.0K	↓ 47.18%
Financing Cash Flow	$-4.8M	↑ 234.88%

	FY19	Y/Y Change
Operating Cash Flow	$-19.4M	↑ 150.04%
Investing Cash Flow	$-883.0K	↑ 49.41%
Financing Cash Flow	$46.5M	↓ 1077.84%

	FY20	Y/Y Change
Operating Cash Flow	$-26.1M	↑ 34.86%
Investing Cash Flow	$-20.0M	↑ 2159.57%
Financing Cash Flow	$46.5M	↑ 0.0%

	FY21	Y/Y Change
Operating Cash Flow	$-10.3M	↓ 60.6%
Investing Cash Flow	$18.9M	↓ 194.83%
Financing Cash Flow	$12.1M	↓ 74.01%

	FY22	Y/Y Change
Operating Cash Flow	$-25.0M	↑ 143.07%
Investing Cash Flow	$-5.0M	↓ 126.61%
Financing Cash Flow	$8.2M	↓ 31.79%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$5.0M	↓ 265.88%
Investing Cash Flow	$4.5M	↓ 4.69%
Financing Cash Flow	$10.4M	↓ 26.7%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-6.9M	↓ 238.51%
Investing Cash Flow	$-16.4M	↓ 462.95%
Financing Cash Flow	$24.7M	↑ 136.42%

Protalix Biotherapeutics Technicals Summary

Sell

Neutral

Buy

Protalix Biotherapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Protalix Biotherapeutics (PLX) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Protalix Biotherapeutics Inc	-4.13%	127.45%	56.76%	45.91%	45.91%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Protalix Biotherapeutics Inc	13.0	NA	-0.1	0.0	-0.27	-0.07	NA	0.44
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Protalix Biotherapeutics Inc	Buy	$170.1M	45.91%	13.0	-21.03%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Protalix Biotherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel.

Organization	Protalix Biotherapeutics
Employees	208
CEO	Mr. Dror Bashan
Industry	Health Services

Management People of Protalix Biotherapeutics

Name	Title
Mr. Dror Bashan	President, CEO & Director
Mr. Eyal Rubin M.B.A.	Senior VP, CFO, Treasurer & Corporate Secretary
Mr. Yaron Naos	Senior Vice President of Operations
Ms. Yael Fellous	Vice President of Human Resources

Important FAQs about investing in PLX Stock from India :

What is Protalix Biotherapeutics share price today?

Protalix Biotherapeutics share price today stands at $2.37, Open: $2.33 ; Previous Close: $2.32 ; High: $2.37 ; Low: $2.32 ; 52 Week High: $2.76 ; 52 Week Low: $0.82.

The stock opens at $2.33, after a previous close of $2.32. The stock reached a daily high of $2.37 and a low of $2.32, with a 52-week high of $2.76 and a 52-week low of $0.82.

Can Indians buy Protalix Biotherapeutics shares?

Yes, Indians can invest in the Protalix Biotherapeutics (PLX) from India.

With INDmoney, you can buy Protalix Biotherapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Protalix Biotherapeutics at zero transaction cost.

How can I buy Protalix Biotherapeutics shares from India?

It is very easy to buy Protalix Biotherapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Protalix Biotherapeutics (PLX) be purchased?

Yes, you can buy fractional shares of Protalix Biotherapeutics with INDmoney app.

What are the documents required to start investing in Protalix Biotherapeutics stocks?

To start investing in Protalix Biotherapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.